Terms: = Kidney tumors AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Prognosis
10 results:
1. serpine1 and its co-expressed genes are associated with the progression of clear cell renal cell carcinoma.
Guo L; An T; Wan Z; Huang Z; Chong T
BMC Urol; 2023 Mar; 23(1):43. PubMed ID: 36959648
[TBL] [Abstract] [Full Text] [Related]
2. Identification and validation of a hypoxia-related prognostic signature in clear cell renal cell carcinoma patients.
Li Z; Du G; Zhao R; Yang W; Li C; Huang J; Wen Z; Li H; Zhang B
Medicine (Baltimore); 2021 Oct; 100(39):e27374. PubMed ID: 34596153
[TBL] [Abstract] [Full Text] [Related]
3. TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma.
Wu P; Xiang T; Wang J; Lv R; Wu G
FEBS Open Bio; 2020 Dec; 10(12):2588-2604. PubMed ID: 33015999
[TBL] [Abstract] [Full Text] [Related]
4. Interactions between TGF-β type I receptor and hypoxia-inducible factor-α mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma.
Mallikarjuna P; Raviprakash TS; Aripaka K; Ljungberg B; Landström M
Cell Cycle; 2019 Sep; 18(17):2141-2156. PubMed ID: 31339433
[TBL] [Abstract] [Full Text] [Related]
5. BIGH3 is overexpressed in clear cell renal cell carcinoma.
Yamanaka M; Kimura F; Kagata Y; Kondoh N; Asano T; Yamamoto M; Hayakawa M
Oncol Rep; 2008 Apr; 19(4):865-74. PubMed ID: 18357369
[TBL] [Abstract] [Full Text] [Related]
6. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Span PN; Witjes JA; Grebenchtchikov N; Geurts-Moespot A; Moonen PM; Aalders TW; Vriesema JL; Kiemeney LA; Schalken JA; Sweep FC
BJU Int; 2008 Jul; 102(2):177-82. PubMed ID: 18336603
[TBL] [Abstract] [Full Text] [Related]
7. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, pai-1, and pai-2].
Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M
Hamostaseologie; 2005 Aug; 25(3):301-10. PubMed ID: 16113755
[TBL] [Abstract] [Full Text] [Related]
8. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract] [Full Text] [Related]
9. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract] [Full Text] [Related]
10. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
[TBL] [Abstract] [Full Text] [Related]
